Michelle L. Mellion Sells 9,260 Shares of PepGen Inc. (NASDAQ:PEPG) Stock

PepGen Inc. (NASDAQ:PEPG) insider Michelle L. Mellion sold 9,260 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $18.19, for a total value of $168,439.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Michelle L. Mellion also recently made the following trade(s):

• On Tuesday, June 11th, Michelle L. Mellion sold 500 shares of PepGen stock. The stock was sold at an average price of $18.04, for a total value of $9,020.00.

PepGen Price Performance

Shares of NASDAQ PEPG traded up $0.23 during midday trading on Wednesday, reaching $17.00. 115,500 shares of the stock traded hands, compared to its average volume of 100,051. The company’s 50 day moving average is $14.72 and its 200 day moving average is $12.33. PepGen Inc. has a one year low of $3.72 and a one year high of $18.72. The stock has a market capitalization of $551.14 million, a PE ratio of -5.27 and a beta of 1.76.

PepGen (NASDAQ:PEPG) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.11. As a group, equities analysts forecast that PepGen Inc. will post -2.87 EPS for the current year.

Institutional Trading of PepGen

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC purchased a new stake in PepGen in the first quarter worth $30,000. Artal Group S.A. purchased a new stake in PepGen in the first quarter worth $2,940,000. Adage Capital Partners GP L.L.C. increased its stake in shares of PepGen by 18.3% during the third quarter. Adage Capital Partners GP L.L.C. now owns 680,000 shares of the company’s stock valued at $3,454,000 after buying an additional 105,000 shares during the period. Vanguard Group Inc. increased its stake in shares of PepGen by 68.0% during the first quarter. Vanguard Group Inc. now owns 850,445 shares of the company’s stock valued at $12,502,000 after buying an additional 344,266 shares during the period. Finally, Janus Henderson Group PLC increased its stake in shares of PepGen by 18.1% during the first quarter. Janus Henderson Group PLC now owns 1,166,642 shares of the company’s stock valued at $17,225,000 after buying an additional 178,438 shares during the period. Hedge funds and other institutional investors own 58.01% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $26.00 target price on shares of PepGen in a research report on Wednesday, May 15th. Wedbush reiterated an “outperform” rating and set a $20.00 target price on shares of PepGen in a research report on Wednesday, May 15th.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.